Yesterday, I lauded the best biopharma CEOs of 2018. Today, I give a side-eye glance to the worst.

To land on this ignominious list, biopharma CEOs had to screw up so badly over the past 12 months to set off my outrage alarm. Serial incompetence is also a qualifier. You’d think I would have trouble finding four nominees. You’d be wrong. The hard part for me is narrowing down the list to just four finalists. Enjoy your reading. You’ll get a chance to vote at the bottom of this post.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • The only 2 CEOs in this contest should be Troy Hamilton and Gary Jacob. The other CEOs mentioned are geniuses compared to these two buffoons

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy